Jiangsu Lianhuan Pharmaceutical (SHA:600513) received approval from China's National Medical Products Administration to conduct clinical trials on relugolix tablets, according to a Shanghai bourse filing on Saturday.
The pharmaceutical company's shares jumped less than 7% at the close of Monday's trade.
Lianhuan will launch a phase III multicenter trial to test the drug as a treatment for prostate cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments